Status Failed — not agreed to
Bill file · 119th Congress
S.Amdt. 5336
To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
Origin Senate · 119th Congress · Submitted Apr. 22, 2026
Sponsors
Sponsor Ron Wyden
History · from the official record
- Offered on the Senate floor Amendment SA 5336 proposed by Senator Wyden. (consideration: CR S1917)
- Failed on the Senate floor Amendment SA 5336 not agreed to in Senate by Yea-Nay Vote. 48 - 50. Record Vote Number: 103.
Record: congress.gov